Pharmaceutical company HaiHe Biopharma has raised $146m in a funding round led by Huagai and backed by investors including OncoCapital and Yingke . PE firm Hua­gai led the round, which al­so in­volved a siz­able group of in­vestors, such as On­co­Cap­i­tal and Yingke PE. The firm is also supported by Hillhouse Capital , RMX Biopharma and the Chinese Academy of Science ’s venture division. Most of the funding will be used to develop the firm’s clinical and preclinical oncology drugs. It has already won approval for more than 10 trials. CSPC Pharma joined forces with Huagai in last March .
Pharmaceutical company HaiHe Biopharma has raised $146m in a funding round led by Huagai and backed by investors including OncoCapital and Yingke . The firm is also supported by Hillhouse Capital , RMX Biopharma and the Chinese Academy of Science ’s venture division. Most of the funding will be used to develop the firm’s clinical and preclinical oncology drugs. It has already won approval for more than 10 trials. CSPC Pharma joined forces with Huagai in last March .